Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors.
Identifieur interne : 001693 ( Main/Curation ); précédent : 001692; suivant : 001694Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors.
Auteurs : Andy Kilianski [États-Unis] ; Susan C. Baker [États-Unis]Source :
- Antiviral research [ 1872-9096 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- isolement et purification : Antiviraux.
- pharmacologie : Antiviraux.
- Animaux, Coronavirus, Humains, Lignée cellulaire, Évaluation préclinique de médicament.
English descriptors
- KwdEn :
- MESH :
- chemical , isolation & purification : Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- drug effects : Coronavirus.
- methods : Drug Evaluation, Preclinical.
- Animals, Cell Line, Humans.
Abstract
To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10years of research on highly pathogenic human coronaviruses."
DOI: 10.1016/j.antiviral.2013.11.004
PubMed: 24269477
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001094
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001094
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001035
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002786
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002786
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002786
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001699
Links to Exploration step
pubmed:24269477Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors.</title><author><name sortKey="Kilianski, Andy" sort="Kilianski, Andy" uniqKey="Kilianski A" first="Andy" last="Kilianski">Andy Kilianski</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C" last="Baker">Susan C. Baker</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, United States. Electronic address: sbaker1@lumc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24269477</idno><idno type="pmid">24269477</idno><idno type="doi">10.1016/j.antiviral.2013.11.004</idno><idno type="wicri:Area/PubMed/Corpus">001094</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001094</idno><idno type="wicri:Area/PubMed/Curation">001094</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001094</idno><idno type="wicri:Area/PubMed/Checkpoint">001035</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001035</idno><idno type="wicri:Area/Ncbi/Merge">002786</idno><idno type="wicri:Area/Ncbi/Curation">002786</idno><idno type="wicri:Area/Ncbi/Checkpoint">002786</idno><idno type="wicri:Area/Main/Merge">001699</idno><idno type="wicri:Area/Main/Curation">001693</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors.</title><author><name sortKey="Kilianski, Andy" sort="Kilianski, Andy" uniqKey="Kilianski A" first="Andy" last="Kilianski">Andy Kilianski</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Baker, Susan C" sort="Baker, Susan C" uniqKey="Baker S" first="Susan C" last="Baker">Susan C. Baker</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, United States. Electronic address: sbaker1@lumc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><series><title level="j">Antiviral research</title><idno type="eISSN">1872-9096</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (isolation & purification)</term><term>Antiviral Agents (pharmacology)</term><term>Cell Line</term><term>Coronavirus (drug effects)</term><term>Drug Evaluation, Preclinical (methods)</term><term>Humans</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (isolement et purification)</term><term>Antiviraux (pharmacologie)</term><term>Coronavirus ()</term><term>Humains</term><term>Lignée cellulaire</term><term>Évaluation préclinique de médicament ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation, Preclinical</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Coronavirus</term><term>Humains</term><term>Lignée cellulaire</term><term>Évaluation préclinique de médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To combat the public health threat from emerging coronaviruses (CoV), the development of antiviral therapies with either virus-specific or pan-coronaviral activities is necessary. An important step in antiviral drug development is the screening of potential inhibitors in cell-based systems. The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) necessitates adapting methods that have been used to identify antivirals against severe acute respiratory syndrome coronavirus (SARS-CoV) and developing new approaches to more efficiently screen antiviral drugs. In this article we review cell-based assays using infectious virus (BSL-3) and surrogate assays (BSL-2) that can be implemented to accelerate antiviral development against MERS-CoV and future emergent coronaviruses. This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10years of research on highly pathogenic human coronaviruses." </div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001693 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001693 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:24269477
|texte= Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:24269477" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |